Ultra rapid lispro (URLi) shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early‐phase study

AIMS: To compare the pharmacokinetics (PK), glucodynamics (GD) and tolerability following single and multiple daily subcutaneous doses of ultra rapid lispro (URLi) and Humalog® in patients with type 2 diabetes mellitus (T2D). MATERIALS AND METHODS: This was a two‐part, randomized, double‐blind Phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Leohr, Jennifer, Kazda, Christof, Liu, Rong, Reddy, Shobha, Dellva, Mary Anne, Matzopoulos, Mark, Loh, Mei Teng, Hardy, Thomas, Klein, Oliver, Kapitza, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297897/
https://www.ncbi.nlm.nih.gov/pubmed/34605142
http://dx.doi.org/10.1111/dom.14561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297897/
https://www.ncbi.nlm.nih.gov/pubmed/34605142
http://dx.doi.org/10.1111/dom.14561

Ejemplares similares